Omnicell (OC9) Stock Overview
Provides healthcare technology in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OC9 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Omnicell, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.80 |
| 52 Week High | US$43.80 |
| 52 Week Low | US$21.60 |
| Beta | 0.79 |
| 1 Month Change | -1.32% |
| 3 Month Change | -19.46% |
| 1 Year Change | -0.67% |
| 3 Year Change | -42.14% |
| 5 Year Change | -74.96% |
| Change since IPO | 239.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| OC9 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -16.3% | -4.2% | -0.6% |
| 1Y | -0.7% | -27.6% | -1.8% |
Return vs Industry: OC9 exceeded the German Medical Equipment industry which returned -27.6% over the past year.
Return vs Market: OC9 exceeded the German Market which returned -1.8% over the past year.
Price Volatility
| OC9 volatility | |
|---|---|
| OC9 Average Weekly Movement | 8.4% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 14.3% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: OC9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OC9's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 3,580 | Randy Lipps | www.omnicell.com |
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services.
Omnicell, Inc. Fundamentals Summary
| OC9 fundamental statistics | |
|---|---|
| Market cap | €1.37b |
| Earnings (TTM) | €1.80m |
| Revenue (TTM) | €1.04b |
Is OC9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OC9 income statement (TTM) | |
|---|---|
| Revenue | US$1.18b |
| Cost of Revenue | US$676.80m |
| Gross Profit | US$508.04m |
| Other Expenses | US$505.99m |
| Earnings | US$2.05m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.045 |
| Gross Margin | 42.88% |
| Net Profit Margin | 0.17% |
| Debt/Equity Ratio | 13.6% |
How did OC9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/14 23:24 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Omnicell, Inc. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| William Sutherland | Benchmark Company |
| Zhilin Long | Berenberg |